BnR Summit 2026

Belt & Road Summit - Deal-Making 2026

9 – 15 Sept 2026 | Hong Kong, China (Hong Kong)

ProjectUpdated on 13 August 2026

Project Title: AI‑driven first‑in‑class antibiotics and novel integrated end‑to‑end solution for H. pylori

Research and Development Scientist at Ynno Med Limited

China (Hong Kong)

About

The global urgent threats of antimicrobial resistance, and H. pylori – a Group 1 carcinogen linked to 90% of gastric cancers, with treatment resistance and no dedicated preventive oral care.

We offer novel antibiotics that act on a new bacterial target sites and show no resistance, alongside the world’s first H. pylori‑specific oral care range proven to inhibit the bacterium, complemented by high‑accuracy diagnostics and therapies.

Key advantages of our novel antibiotics include low toxicity, validated in vivo efficacy, strong patent protection.  For H. pylori Nobel laureate collaboration, and a complete prevention‑diagnosis‑treatment pipeline, all aim at reducing antibiotic resistance and gastric cancer risk.

Project Location

  • China (Hong Kong)

Project Website

https://www.ynnomed.com/

Project Format

  • Private Project

Go Global Project

  • Yes

ESG (Environmental, Social, and Governance)

  • Yes

Project Stage

  • Investment / Financing Discussion

Main Project Sector

  • Technology

Technology

  • Bio-Tech
  • Health Technology
  • Medical Technology

Urban Development

  • Health Facilities

Type(s) of Last Financing Round of the project (if Applicable)

  • Government & Public Funding

Main Service(s) Required

  • Financial Services

Organisation

Ynno Med Limited

China (Hong Kong)

Similar opportunities